Company / R&D Expense
Fulcrum Therapeutics, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$56.1M
FY2025
5-year range
$56.1M / $76.8M
FY2021-FY2025
Trend
-11.5%
vs FY2024
Sector context
#176 of 210
Health Care
What the data says
Fulcrum Therapeutics, Inc.'s r&d expense of $56M is lower than 84% of companies in the Health Care sector (FY2025). R&D Expense has declined for 3 consecutive years, from $77M in FY2022 to $56M in FY2025.
Based on SEC 10-K filings.
$56M in FY2025 with a 5-year CAGR of -1.0%.
Declined from $72M to $56M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -9.9%
- 5-Year CAGR
- -1.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 210This company $56.1M Sector average $644.1M
▼
-91.3% below sector average
Key checks
Key Insights
- Fulcrum Therapeutics, Inc.'s r&d expense has declined for 3 consecutive years.
- 5-year CAGR of -1.0%, indicating a declining trend.
- In FY2025, r&d expense decreased 11.5% year-over-year.
- Ranks #176 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $56.1M | -11.5% |
| FY2024 | $63.4M | -11.7% |
| FY2023 | $71.8M | -6.5% |
| FY2022 | $76.8M | +10.2% |
| FY2021 | $69.7M | +18.1% |
| FY2020 | $59.0M | -16.9% |
| FY2019 | $71.1M | +182.2% |
| FY2018 | $25.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026